BiopharmaBLTE

Belite Bio

Belite Bio is a clinical-stage biopharmaceutical company developing oral therapies for degenerative retinal diseases, led by the RBP4 antagonist tinlarebant for Stargardt disease and geographic atrophy.

Forecast a trial in the Arena Browse all benchmarks

Trials tracked

Resolved

Drugs

Diseases

Belite Bio forecasting benchmarks

1 benchmark

ResolvedPhase 3

DRAGON Phase 3: tinlarebant (5 mg daily) in adolescent Stargardt disease type 1 (STGD1)

Tinlarebant · Stargardt disease

Dec 1, 2025Clinical Trials

Pipeline on the platform

Tinlarebant· Oral small molecule

Therapeutic areas

Stargardt disease· STGD1

About Belite Bio

What is Belite Bio developing?

Which Belite Bio trials can I forecast?

We track 1 Belite Bio trial readout as AI forecasting benchmarks. Open any benchmark to predict the outcome or see how models scored.

References

Keep exploring

All benchmarks Diseases Drugs Targets & genes